Ernexa Therapeutics Inc. ERNA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1991-08-29
Ernexa Therapeutics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 83.5% | -247.1% | — | — | — | — | — | — | — |
| Operating margin | — | -2693.1% | -31080.9% | — | — | -456.7% | -8.9% | 0.9% | -6.6% | -10.2% |
| Net margin | — | -7652.7% | -31864.7% | — | — | -457.4% | -10.3% | -1.1% | -5.1% | -13.1% |
| FCF margin | — | -2784.4% | -30039.7% | — | — | -140.3% | 13.2% | 3.1% | -0.8% | -1.8% |
| Return on assets | -241.4% | -845.3% | -44.1% | -110.3% | -388.7% | -192.6% | -14.5% | -1.7% | -6.5% | -17.5% |
| Return on equity | -586.6% | -2618.4% | -970.4% | -203.0% | -480.5% | -346.4% | -21.0% | -3.7% | -19.5% | -71.9% |
| Debt / equity | — | — | — | — | — | 0.07× | — | 0.54× | 0.93× | 1.99× |
| Current ratio | 1.01 | 0.80 | 1.46 | 1.79 | 5.10 | 0.55 | 1.00 | 1.69 | 0.90 | 1.60 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.